AstraZeneca PLC (A1ZN34)
Sao Paulo Exchange · Brazil · prices in BRL · close of 22 Oct 2026
Key indicators
| Last close | BRL 144.72 |
|---|---|
| 52-week range | 129.48 – 190.40 |
| Return, 1 month / 3 months | −2.8% / +1.6% |
| Return, 1 year / 3 years | −2.7% / +39.8% |
| Trend | Below its 200-day average |
| RSI (14) | 59 |
| Volatility (1 year) | 32.8% |
| Worst drawdown (1 year) | -27.5% |
| Average daily value traded | 0.09M BRL |
| Dividend yield | 12.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
AstraZeneca is a pharmaceutical company that researches, develops and makes prescription medicines. Its work covers cancer treatments, heart and metabolic conditions, respiratory disease and other serious illnesses. The company supplies its products to hospitals, doctors and healthcare systems in many countries, and it also has a vaccines and immune therapies business. AstraZeneca is based in Cambridge, England, and operates research and manufacturing sites around the world.
AstraZeneca PLC is represented on the Sao Paulo Exchange in Brazil by a Brazilian depositary receipt (BDR) under the code A1ZN34, with its price quoted in Brazilian reais (BRL). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
AstraZeneca PLC (A1ZN34) trades on the Sao Paulo Exchange in Brazil. It last closed at BRL 144.72 on 22 October 2026.
Its price-based Market X-Ray is 47 out of 100 (a weak price profile), ranking 838 of 1,454 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 2.7% and over the last three months it rose 1.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Sao Paulo Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 31 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -5.9% | ||
| From 52-week high | -20.4% | ||
| Momentum | 40 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 1.6% | ||
| 6-month return | -10.0% | ||
| 12-month return, skipping the last month | 0.2% | ||
| Stability (higher is calmer) | 58 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 32.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -27.5% | ||
| Liquidity | 58 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.09M BRL | ||
| Zero-volume days | 0.0% | ||
| Income | 58 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 12.6% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | +2.1% |
|---|---|
| 1 month | −2.8% |
| 3 months | +1.6% |
| 6 months | −10.0% |
| 1 year | −2.7% |
| 3 years | +39.8% |
| 5 years | +34.1% |
Signals
| 50-day / 200-day average | 139.43 / 153.79 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 3.22 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 5 Aug 2026 | GBP 0.8707 |
| 18 Feb 2026 | GBP 1.8380 |
| 6 Aug 2025 | GBP 0.2207 |
| 19 Feb 2025 | GBP 0.4727 |
| 7 Aug 2024 | GBP 0.2219 |
| 21 Feb 2024 | GBP 0.3875 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Sao Paulo Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.